Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16195632 | 0.94 | — | — | |
| SCHEMBL15059725 | 0.89 | — | — | |
| SCHEMBL15058193 | 0.88 | — | — | |
| SCHEMBL15059670 | 0.88 | — | — | |
| SCHEMBL15059493 | 0.87 | — | — | |
| SCHEMBL15058547 | 0.86 | — | — | |
| SCHEMBL15059821 | 0.86 | — | — | |
| SCHEMBL15059827 | 0.86 | — | — | |
| SCHEMBL15058330 | 0.86 | — | — | |
| SCHEMBL15059153 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794569-B1 | HETEROCYCLIC UREA COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-05-10 | — | — | EP | claimed |
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | claimed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | claimed |
| EP-2794569-A1 | HETEROCYCLIC UREA COMPOUNDS | Biota Europe Ltd (GB) | 2014-10-29 | — | — | EP | claimed |
| WO-2013091011-A1 | HETEROCYCLIC UREA COMPOUNDS | BIOTA EUROPE LTD (GB) | 2013-06-27 | — | — | WO | claimed |
| EP-2794569-B1 | HETEROCYCLIC UREA COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-05-10 | — | — | EP | disclosed |
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | disclosed |
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | disclosed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | UMPS, URB2, UROD | IRAK4 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.